Breast Cancer Resources

The very first sign people notice is often a lump or thickening in the breast or underarm area — this is what prompts most initial doctor visits. However, it's important to know that many early breast cancers produce no symptoms at all, which is why routine mammograms are so critical. Other early signs that may appear include:

• A new lump or mass in the breast (which may feel hard, irregular, or even soft/rounded)
• Swelling of part or all of the breast, even without a distinct lump
• Skin changes — dimpling, puckering, or a texture resembling an orange peel (peau d'orange)
• Nipple changes — inversion (pulling inward), discharge (especially bloody or clear without squeezing), or redness
• Unexplained breast or nipple pain that is persistent
• Changes in breast size or shape

As reflected in Manta Cares patient journeys, many patients first became aware of signs through a routine breast exam at a doctor's office, which then led to a referral for a diagnostic mammogram. Importantly, one patient user noted a month-long wait between her breast exam and scheduled mammogram – a reminder to advocate for earlier scheduling if you notice something concerning. Another reminder – a breast mass that is present for more than a month, even with a mammogram that is reported as “normal,” may still be concerning. Work with your doctor and health care team to stay on top of breast masses that don’t go away.

There are several atypical symptoms many patients miss:

• Back or shoulder pain — cancer that has spread to lymph nodes or bones may present as shoulder or upper back pain
• Itching, rash, or warmth — these can be signs of inflammatory breast cancer, a rarer but aggressive type
• Skin that looks bruised or red with no injury history
• Unexplained rapid weight loss — flagged in Manta Cares conversations as a warning sign needing urgent workup
• Severe fatigue — one Manta Cares patient came in with progressive fatigue, which led to the discovery of a breast mass
• Lymph node swelling in the armpit without a known infection

The key takeaway from patient experiences on the Manta Cares platform: Some of these signs and symptoms are normal, especially if they resolve within a few days. However, if they persist longer than two weeks, don't wait to see if a new or unusual symptom
resolves on its own. Track it, document when it started, and bring it to your care team’s attention.

BI-RADS stands for Breast Imaging Reporting and Data System. It's a standardized scoring system radiologists use when reporting mammogram, ultrasound, and MRI results — it tells you how suspicious a finding is and what action is recommended.

BI-RADS Category: 0
Meaning: Incomplete — the imaging was not satisfactory, usually for technical reasons. Repeat imaging needed
Recommended Action: Return for more imaging

BI-RADS Category: 1
Meaning: Negative — nothing of concern found
Recommended Action: Routine screening

BI-RADS Category: 2
Meaning: Benign finding — definitely not cancer
Recommended Action: Routine screening

BI-RADS Category: 3
Meaning: Probably benign (< 2% chance of malignancy)
Recommended Action: Short-interval follow-up (6 months)

BI-RADS Category: 4
Meaning: Suspicious — biopsy recommended
Recommended Action: Biopsy (subcategories 4A, 4B, 4C reflect increasing suspicion)

BI-RADS Category: 5
Meaning: Highly suggestive of malignancy (≥ 95% chance)
Recommended Action: Biopsy required

BI-RADS Category: 6
Meaning: Known biopsy-proven malignancy
Recommended Action: Treatment planning

BI-RADS 5 means the imaging finding is highly suspicious for cancer — the radiologist sees characteristics such as irregular shape, spiculated margins (lines or streaks radiating outward from the edges of a mass, often appearing star-shaped), or calcifications that are strongly associated with malignancy. This does not mean you have cancer with certainty — a biopsy is still required to confirm the diagnosis. However, you should act quickly. As noted in Manta Cares patient conversations, one user received her mammogram results on a Thursday and had her biopsy scheduled for the following week — timeframes can move fast at this stage.

Manta Cares even has a dedicated BI-RADS station on the cancer map, and a widely read blog post specifically about BI-RADS 5, because this is one of the most anxiety-inducing and confusing results patients receive.

The period immediately after diagnosis is one of the most overwhelming moments patients describe on the Manta Cares platform. Here's a realistic timeline of what to expect:

Immediately (Days 1–2 weeks):

• Absorbing the emotional shock — fear, disbelief, and anxiety are completely normal
• Multiple appointments begin: surgical oncologist, medical oncologist, radiation oncologist, sometimes plastic or reconstructive surgeon, nutritionist, and genetic counselor
• Additional imaging, such as magnetic resonance imaging (MRI), a positron emission tomography (PET) scan, or a computed tomography (CT) scan, to understand the full extent of the cancer
• Pathology review to confirm receptor status (ER/PR/HER2), grade, and other markers
• Genetic testing discussion (BRCA1/BRCA2 and others)

In the first few weeks:

• Staging — understanding how far the cancer has spread (see Cancer Stages section)
• Treatment planning with your multidisciplinary team
• Major decisions: surgery type (lumpectomy vs. mastectomy), sequencing of treatment (chemo or endocrine treatment before or after surgery), reconstruction options

As patient Ryan shared on the platform: "Before you actually start treatment, you meet with myriad different specialists... it's just overwhelming, trying to keep up with all of the various appointments."

Practical tip: The Manta Cares Appointment Notebook and cancer map are specifically designed to help you track this wave of
appointments, organize questions for each specialist, and understand where you are in your journey at every step.

Breast cancers are classified by where they start, how they behave, and their receptor profile.

By location:

• Ductal Carcinoma In Situ (DCIS) — non-invasive; cancer cells are inside the milk ducts but haven't spread. Considered "Stage 0."
• Invasive Ductal Carcinoma (IDC) — most common type; starts in ducts and invades surrounding tissue
• Invasive Lobular Carcinoma (ILC) — starts in the lobules (milk-producing glands)
• Inflammatory Breast Cancer (IBC) — rare and aggressive; blocks lymph vessels, causing breast redness, swelling, warmth
• Paget's Disease of the Breast — involves the nipple and areola skin
• Phyllodes Tumors — rare tumors of the connective tissue
  

By receptor profile (critical for treatment decisions):

• Hormone Receptor-Positive (HR+): ER-positive and/or PR-positive — treated with hormone-blocking therapies (tamoxifen, aromatase inhibitors)
• HER2-Positive: Overexpresses the HER2 protein — treated with targeted therapies (trastuzumab/Herceptin and others)
• Triple Negative Breast Cancer (TNBC): No estrogen, progesterone, or HER2 receptors — the most aggressive subtype, primarily treated with chemotherapy and immunotherapy (e.g., Keytruda/pembrolizumab and others)
• Triple Positive: ER+, PR+, and HER2+ — can be treated with both hormone therapy and HER2-targeted therapy

Manta Cares has dedicated cancer maps for early-stage hormone-positive, HER2+, and triple-negative breast cancer, as well as metastatic breast cancer — each with different treatment pathways.

Yes, men can absolutely develop breast cancer. Though rare (about 1% of all breast cancer cases), it is a real diagnosis. Men have a small amount of breast tissue, which makes them susceptible.

How symptoms may present differently in men:

• A hard, painless lump beneath the nipple is the most common presentation (men have less breast tissue, so lumps are often more immediately noticeable)
• Nipple changes — discharge (sometimes bloody), retraction, or ulceration of the nipple skin
• Skin changes over the chest/nipple area — dimpling, redness, scaling
• Because men are not typically screened and often don't think of breast cancer as something that affects them, diagnoses tend to come later — making awareness critical

Risk factors in men include BRCA2 gene mutations, elevated estrogen levels (from obesity, liver disease, or certain medications), Klinefelter syndrome, family history, and radiation exposure to the chest.

Treatment depends heavily on cancer type, stage, receptor status, and individual health factors. Manta Cares' cancer maps lay out these branching treatment pathways visually. The main options include:

Surgery:

• Lumpectomy (breast-conserving surgery) — removes the tumor and a margin of surrounding tissue; typically followed by radiation
• Mastectomy — removes one (unilateral) or both (bilateral) breasts; may be chosen for genetic risk, tumor size, or patient preference
• Sentinel node biopsy / axillary lymph node dissection — checks whether cancer has spread to lymph nodes
  

Systemic Therapies:

• Chemotherapy — used before surgery (neoadjuvant) to shrink tumors or after surgery (adjuvant) to reduce recurrence risk; common regimens include AC-T (doxorubicin + cyclophosphamide, then taxane), or carboplatin-based regimens for TNBC
• Hormone (endocrine) therapy — for HR+ cancers: tamoxifen (pre-menopausal) or aromatase inhibitors like anastrozole, letrozole, exemestane (post-menopausal)
• Targeted therapy — for HER2+ cancers: trastuzumab (Herceptin), pertuzumab, T-DM1/T-DXd
• Immunotherapy — for TNBC: pembrolizumab (Keytruda) combined with chemotherapy
• CDK4/6 inhibitors — for metastatic HR+: palbociclib, ribociclib, abemaciclib (Verzenio)

Radiation:

• Usually follows lumpectomy; sometimes recommended after mastectomy, depending on tumor size and node involvement

As one Manta Cares nurse noted in a patient call, for TNBC specifically, the pathological complete response (pCR) — meaning no cancer cells remaining after neoadjuvant treatment — is a key milestone that shapes decisions about post-surgical therapy.

This varies, but here is a realistic picture drawn from Manta Cares patient experiences:

• Diagnosis to first appointment with oncologist: Typically 1–2 weeks (though one patient waited longer due to her oncologist's unavailability)
• Diagnosis to treatment start: Generally 3–6 weeks for most patients, though this depends on the type and aggressiveness of the cancer
• For slow-growing cancers (e.g., Grade 1, HR+): There may be more time — one Manta Cares patient with a Grade 1 diagnosis had several weeks between biopsy and starting chemotherapy, during which she met with multiple specialists
• For aggressive cancers (e.g., TNBC, HER2+, inflammatory): Teams typically move faster, sometimes within 1–2 weeks of diagnosis

Key things that affect timing: additional imaging may be needed, genetic testing results, insurance authorization for medications, and whether surgery or chemotherapy comes first.

Important reminder: Use this waiting period wisely. It's a valuable time to gather information, seek a second opinion, or have your case discussed at a tumor board, and get clear on your treatment plan — not a sign that the situation isn't serious. It’s better to take an extra week to get the plan right than to rush into a plan that doesn’t feel right.

Manta Cares conversations highlight that bilateral mastectomy is among the most significant decisions patients face. Here's what to know:

Before surgery:

• Understand your options: unilateral vs. bilateral, with or without immediate reconstruction
• Get genetic testing results (BRCA1/2) — these significantly influence the decision
• Discuss reconstruction options with a plastic (reconstructive) surgeon before surgery: implant-based vs. flap-based (e.g., DIEP flap, which uses abdominal tissue)
• Get all dental work done prior to starting any chemotherapy if that comes first
• Arrange your home for recovery: many patients recommend getting a recliner chair to help prop up and sleep comfortably post-surgery
• Stock up on loose, front-opening clothing; avoid anything pulled over the head

Practical and emotional prep:

• Arrange for a support person (caregiver) who can be present and help — Manta Cares has dedicated caregiver support resources
• Talk with your care team about drains — surgical drains are common post-mastectomy and require daily care
• Ask about physical therapy referrals post-surgery for range-of-motion and lymphedema prevention
• Understand the signs of post-surgical complications: infection, seroma (fluid buildup), lymphedema

One patient preparing for a bilateral mastectomy on the platform shared that she was also asking how to help manage her husband's anxiety — a reminder that preparation is emotional as well as physical.

Important reminder: For most patients, the odds of having the cancer come back may not be reduced by mastectomy. Lumpectomy may be equally beneficial in terms of cancer treatment: More is not always better.

Tamoxifen is a selective estrogen receptor modulator (SERM) used for hormone receptor-positive (ER+/PR+) breast cancer. It blocks estrogen from binding to cancer cells and is typically prescribed for 5–10 years.

Key things to know:

Who takes it: Most often prescribed for pre-menopausal women (or men) with HR+ breast cancer. Post-menopausal women are more often prescribed aromatase inhibitors (anastrozole, letrozole, exemestane), though tamoxifen is still used.

How to take it: Usually once daily, taken at the same time each day, with or without food.

Common side effects:

• Hot flashes (very common — the most frequently reported side effect)
• Vaginal dryness, discharge, or irritation
• Mood changes, depression
• Fatigue
• Irregular periods or cessation of periods (in pre-menopausal women)
• Weight changes
• Joint and muscle aches

Less common but serious risks to discuss with your doctor:

• Blood clots (deep vein thrombosis, pulmonary embolism) — tamoxifen slightly increases this risk; report leg swelling, pain, or shortness of breath immediately
• Uterine (endometrial) cancer — tamoxifen can stimulate the uterine lining; report any unusual vaginal bleeding promptly
• Cataracts — eye exams are recommended

Important drug interactions: Certain antidepressants (especially paroxetine/Paxil and fluoxetine/Prozac) can interfere with tamoxifen's metabolism and reduce its effectiveness. Discuss all medications with your oncologist.

Adherence matters: Studies show that consistent, long-term use significantly reduces recurrence risk. If side effects are intolerable, talk to your oncologist — there may be options to manage them or switch to a different endocrine therapy rather than stopping.